"This is bad news for the field. After my experience with business analysts at the official press conference after my presentation at the AAN, on the pivotal oral cladribine results, I made a conscious decision not to speak to business analysts in private. Unfortunately, you can't avoid them at conferences. When you present market sensitive results either as a platform presentation, or as a poster, more than 50% of the people wanting additional information are either business analysts or pharma employees from competitive companies. It is very difficult, if not impossible, to define any safe ground with them. Saying no is easier than justifying why you said yes; and it is obviously worse if you get paid $1,000 per hour for saying yes."
"And we (neurologists) wonder why we have lost, or are losing, credibility. These types of stories provide the fodder for the conspiracy theories that underpin the CCSVI anti-science campaign! "